Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01355679 · ClinicalTrials.gov registry record · NA
Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma
A NA study, sponsored by Giselle Sholler.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT01355679 is a NA study that has completed, run by Giselle Sholler. The registered enrollment target is 16 participants.
The verdict
NCT01355679, a NA study, has completed, sponsored by Giselle Sholler.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to test the feasibility (ability to be done) of an experimental test to help plan your cancer treatment. This study plan is not studying the effectiveness of the proposed combinations of therapy for your cancer that you may receive after the experimental testing. This study will look at an experimental technology to determine a tumor's molecular makeup (gene expression profile). This technology (called "OncInsights") is being used to discover new ways to understand cancers and potentially predict the best treatments for patients with cancer in the future. The experimental technology has not been approved by the U.S. Food and Drug Administration.
Interventions
- DEVICE Guided Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2011-05 |
| Est. Completion | 2015-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01355679
The ClinicalTrials.gov registry entry for NCT01355679 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Giselle Sholler, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Guided Therapy is the first listed.
NCT01355679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01355679 about?
NCT01355679 is a clinical study titled "Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma". The purpose of this study is to test the feasibility (ability to be done) of an experimental test to help plan your cancer treatment. This study plan is not studying the effectiveness of the proposed combinations of therapy for your cancer that you may receive after the experimental testing. This s...
What is the current status of trial NCT01355679?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2011-05. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01355679?
The interventions under investigation include: Guided Therapy (DEVICE).
Who is sponsoring clinical trial NCT01355679?
This trial is sponsored by Giselle Sholler, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.